The European Patent Office published application EP3762485A1 on March 25, 2026, for Conagen Inc. covering C12N 9/00 and C12P 21/00 technologies related to engineered organisms and methods for producing glycomolecules with reduced sulfation. The patent designates 31 European states including major markets such as Germany, France, United Kingdom, Italy, Netherlands, Spain, Poland, Sweden, and others.

This is a routine patent publication that does not impose new regulatory obligations. Companies operating in biotechnology or pharmaceutical manufacturing sectors working with glycomolecules or sulfation processes should review the patent claims to assess potential licensing or infringement considerations. No immediate compliance actions are required.